Literature DB >> 20591081

Management of visceral leishmaniasis in rural primary health care services in Bihar, India.

E Hasker1, S P Singh, P Malaviya, R P Singh, R Shankar, M Boelaert, S Sundar.   

Abstract

OBJECTIVE: In 2005 a visceral leishmaniasis (VL) elimination initiative was launched on the Indian subcontinent, with early diagnosis based on a rapid diagnostic test and treatment with the oral drug miltefosine as its main strategy. Several recent studies have signaled underreporting of VL cases in the region. Information on treatment outcomes is scanty. Our aim was to document VL case management by the primary health care services in India.
METHODS: We took a random sample of all VL patients registered in rural primary health care (PHC) facilities of Muzaffarpur district, Bihar, India during 2008. Patients were traced at home for an interview and their records were reviewed. We recorded patient and doctor delay, treatment regimens, treatment outcomes and costs incurred by patients.
RESULTS: We could review records of all 150 patients sampled and interview 139 patients or their guardian. Most patients (81%) had first presented to unqualified practitioners; median delay before reaching the appropriate primary healthcare facility was 40 days (IQR 31-59 days). Existing networks of village health workers were under-used. 48% of VL patients were treated with antimonials; 40% of those needed a second treatment course. Median direct expenditure by patients was 4000 rupees per episode (IQR 2695-5563 rupees), equivalent to almost 2 months of household income.
CONCLUSION: In 2008 still critical flaws remained in VL case management in the primary health care services in Bihar: obsolete use of antimonials with high failure rates and long patient delay. To meet the target of the VL elimination, more active case detection strategies are needed, and village health worker networks could be more involved. Costs to patients remain an obstacle to early case finding.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20591081      PMCID: PMC3010850          DOI: 10.1111/j.1365-3156.2010.02562.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  13 in total

1.  Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India.

Authors:  Paul G Barnett; S P Singh; Caryn Bern; Allen W Hightower; Shyam Sundar
Journal:  Am J Trop Med Hyg       Date:  2005-10       Impact factor: 2.345

Review 2.  Innovative lead discovery strategies for tropical diseases.

Authors:  Solomon Nwaka; Alan Hudson
Journal:  Nat Rev Drug Discov       Date:  2006-11       Impact factor: 84.694

3.  Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.

Authors:  Filip Meheus; Marleen Boelaert; Rob Baltussen; Shyam Sundar
Journal:  Trop Med Int Health       Date:  2006-11       Impact factor: 2.622

4.  Estimation of under-reporting of visceral leishmaniasis cases in Bihar, India.

Authors:  Vijay P Singh; Alok Ranjan; Roshan K Topno; Rakesh B Verma; Niyamat A Siddique; Vidya N Ravidas; Narendra Kumar; Krishna Pandey; Pradeep Das
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

5.  Inequity in health care delivery in India: the problem of rural medical practitioners.

Authors:  Rashmi Kumar; Vijay Jaiswal; Sandeep Tripathi; Akshay Kumar; M Z Idris
Journal:  Health Care Anal       Date:  2007-09

6.  Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India.

Authors:  S P Singh; D C S Reddy; M Rai; S Sundar
Journal:  Trop Med Int Health       Date:  2006-06       Impact factor: 2.622

Review 7.  Visceral leishmaniasis control: a public health perspective.

Authors:  M Boelaert; B Criel; J Leeuwenburg; W Van Damme; D Le Ray; P Van der Stuyft
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Sep-Oct       Impact factor: 2.184

8.  Resistance to treatment in Kala-azar: speciation of isolates from northeast India.

Authors:  S Sundar; K Pai; R Kumar; K Pathak-Tripathi; A A Gam; M Ray; R T Kenney
Journal:  Am J Trop Med Hyg       Date:  2001-09       Impact factor: 2.345

9.  Risk mapping of visceral leishmaniasis: the role of local variation in rainfall and altitude on the presence and incidence of kala-azar in eastern Sudan.

Authors:  Dia-Eldin A Elnaiem; Judith Schorscher; Anna Bendall; Valérie Obsomer; Maha E Osman; Abdelrafie M Mekkawi; Stephen J Connor; Richard W Ashford; Madeleine C Thomson
Journal:  Am J Trop Med Hyg       Date:  2003-01       Impact factor: 2.345

10.  Risk factors for kala-azar in Bangladesh.

Authors:  Caryn Bern; Allen W Hightower; Rajib Chowdhury; Mustakim Ali; Josef Amann; Yukiko Wagatsuma; Rashidul Haque; Katie Kurkjian; Louise E Vaz; Moarrita Begum; Tangin Akter; Catherine B Cetre-Sossah; Indu B Ahluwalia; Ellen Dotson; W Evan Secor; Robert F Breiman; James H Maguire
Journal:  Emerg Infect Dis       Date:  2005-05       Impact factor: 6.883

View more
  17 in total

1.  Village health workers in Bihar, India: an untapped resource in the struggle against kala-azar.

Authors:  P Malaviya; E Hasker; R P Singh; J P Van Geertruyden; M Boelaert; S Sundar
Journal:  Trop Med Int Health       Date:  2012-12-20       Impact factor: 2.622

2.  Health & Demographic Surveillance System profile: the Muzaffarpur-TMRC Health and Demographic Surveillance System.

Authors:  Paritosh Malaviya; Albert Picado; Epco Hasker; Bart Ostyn; Sangeeta Kansal; Rudra Pratap Singh; Ravi Shankar; Marleen Boelaert; Shyam Sundar
Journal:  Int J Epidemiol       Date:  2014-09-02       Impact factor: 7.196

3.  Monitoring drug effectiveness in kala-azar in Bihar, India: cost and feasibility of periodic random surveys vs. a health service-based reporting system.

Authors:  P Malaviya; R P Singh; S P Singh; E Hasker; B Ostyn; R Shankar; M Boelaert; S Sundar
Journal:  Trop Med Int Health       Date:  2011-05-30       Impact factor: 2.622

Review 4.  Elimination of visceral leishmaniasis on the Indian subcontinent.

Authors:  Om Prakash Singh; Epco Hasker; Marleen Boelaert; Shyam Sundar
Journal:  Lancet Infect Dis       Date:  2016-09-28       Impact factor: 25.071

5.  Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.

Authors:  Meghan R Perry; Susan Wyllie; Andrea Raab; Joerg Feldmann; Alan H Fairlamb
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

6.  Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs.

Authors:  Shri Prakash Singh; Siddhivinayak Hirve; M Mamun Huda; Megha Raj Banjara; Narendra Kumar; Dinesh Mondal; Shyam Sundar; Pradeep Das; Chitra Kumar Gurung; Suman Rijal; C P Thakur; Beena Varghese; Axel Kroeger
Journal:  PLoS Negl Trop Dis       Date:  2011-02-08

7.  Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008.

Authors:  Paritosh Malaviya; Albert Picado; Shri Prakash Singh; Epco Hasker; Rudra Pratap Singh; Marleen Boelaert; Shyam Sundar
Journal:  PLoS One       Date:  2011-03-04       Impact factor: 3.240

8.  Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?

Authors:  Meghan R Perry; Susan Wyllie; Vijay Kumar Prajapati; Joerg Feldmann; Shyam Sundar; Marleen Boelaert; Alan H Fairlamb
Journal:  PLoS Negl Trop Dis       Date:  2011-09-27

9.  Visceral leishmaniasis clinical management in endemic districts of India, Nepal, and bangladesh.

Authors:  Megha Raj Banjara; Siddhivinayak Hirve; Niyamat Ali Siddiqui; Narendra Kumar; Sangeeta Kansal; M Mamun Huda; Pradeep Das; Suman Rijal; Chitra Kumar Gurung; Paritosh Malaviya; Byron Arana; Axel Kroeger; Dinesh Mondal
Journal:  J Trop Med       Date:  2012-05-09

10.  Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India.

Authors:  Anette Stauch; Hans-Peter Duerr; Jean-Claude Dujardin; Manu Vanaerschot; Shyam Sundar; Martin Eichner
Journal:  PLoS Negl Trop Dis       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.